Methyl-CpG-binding domain proteins: readers of the epigenome

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Bestor T, Laudano A, Mattaliano R, Ingram V. Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases. J. Mol. Biol. 203(4), 971–983 (1988).
  Medline CASGoogle Scholar
• 2 Stirzaker C, Taberlay PC, Statham AL, Clark SJ. Mining cancer methylomes: prospects and challenges. Trends Genet. 30(2), 75–84 (2014).
  Medline CASGoogle Scholar
• 3 Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J. Mol. Biol. 196(2), 261–282 (1987).
  Medline CASGoogle Scholar
• 4 Ogoshi K, Hashimoto S, Nakatani Y et al. Genome-wide profiling of DNA methylation in human cancer cells. Genomics 98(4), 280–287 (2011).
  Medline CASGoogle Scholar
• 5 Ball MP, Li JB, Gao Y et al. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat. Biotechnol. 27(4), 361–368 (2009).
  Medline CASGoogle Scholar
• 6 Taberlay PC, Statham AL, Kelly TK, Clark SJ, Jones PA. Reconfiguration of nucleosome-depleted regions at distal regulatory elements accompanies DNA methylation of enhancers and insulators in cancer. Genome Res. 24(9), 1421–1432 (2014).
  Medline CASGoogle Scholar
• 7 Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat. Genet. 19(3), 219–220 (1998).
  Medline CASGoogle Scholar
• 8 Bogdanovic O, Veenstra GJ. DNA methylation and methyl-CpG binding proteins: developmental requirements and function. Chromosoma 118(5), 549–565 (2009).
  Medline CASGoogle Scholar
• 9 Hashimoto H, Vertino PM, Cheng X. Molecular coupling of DNA methylation and histone methylation. Epigenomics 2(5), 657–669 (2010).
  CASGoogle Scholar
• 10 Filion GJ, Zhenilo S, Salozhin S, Yamada D, Prokhortchouk E, Defossez PA. A family of human zinc finger proteins that bind methylated DNA and repress transcription. Mol. Cell. Biol. 26(1), 169–181 (2006).
  Medline CASGoogle Scholar
• 11 Unoki M, Nishidate T, Nakamura Y. ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene 23(46), 7601–7610 (2004).
  Medline CASGoogle Scholar
• 12 Prokhortchouk A, Hendrich B, Jorgensen H et al. The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional repressor. Genes Dev. 15(13), 1613–1618 (2001).
  Medline CASGoogle Scholar
• 13 Hendrich B, Bird A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol. Cell. Biol. 18(11), 6538–6547 (1998).•• Discovery and initial characterization of MeCP2 and MBD1–4.
  Medline CASGoogle Scholar
• 14 Pastor WA, Aravind L, Rao A. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat. Rev. Mol. Cell Biol. 14(6), 341–356 (2013).
  Medline CASGoogle Scholar
• 15 Baymaz HI, Fournier A, Laget S et al. MBD5 and MBD6 interact with the human PR-DUB complex through their methyl-CpG-binding domain. Proteomics 14(19), 2179–2189 (2014).
  Medline CASGoogle Scholar
• 16 Hendrich B, Tweedie S. The methyl-CpG binding domain and the evolving role of DNA methylation in animals. Trends Genet. 19(5), 269–277 (2003).
  Medline CASGoogle Scholar
• 17 Nan X, Meehan RR, Bird A. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Res. 21(21), 4886–4892 (1993).
  Medline CASGoogle Scholar
• 18 Ohki I, Shimotake N, Fujita N et al. Solution structure of the methyl-CpG binding domain of human MBD1 in complex with methylated DNA. Cell 105(4), 487–497 (2001).
  Medline CASGoogle Scholar
• 19 Boeke J, Ammerpohl O, Kegel S, Moehren U, Renkawitz R. The minimal repression domain of MBD2b overlaps with the methyl-CpG-binding domain and binds directly to Sin3A. J. Biol. Chem. 275(45), 34963–34967 (2000).
  Medline CASGoogle Scholar
• 20 Wade PA, Gegonne A, Jones PL, Ballestar E, Aubry F, Wolffe AP. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat. Genet. 23(1), 62–66 (1999).
  Medline CASGoogle Scholar
• 21 Ng HH, Jeppesen P, Bird A. Active repression of methylated genes by the chromosomal protein MBD1. Mol. Cell. Biol. 20(4), 1394–1406 (2000).
  Medline CASGoogle Scholar
• 22 Meehan RR, Lewis JD, Bird AP. Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res. 20(19), 5085–5092 (1992).
  Medline CASGoogle Scholar
• 23 Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J. Biol. Chem. 278(6), 4035–4040 (2003).
  Medline CASGoogle Scholar
• 24 Nan X, Ng HH, Johnson CA et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393(6683), 386–389 (1998).• One of the first papers to describe that methyl-binding domain (MBD) protein activity is mediated by protein partners.
  Medline CASGoogle Scholar
• 25 Kernohan KD, Vernimmen D, Gloor GB, Berube NG. Analysis of neonatal brain lacking ATRX or MeCP2 reveals changes in nucleosome density, CTCF binding and chromatin looping. Nucleic Acids Res. 42(13), 8356–8368 (2014).
  Medline CASGoogle Scholar
• 26 Agarwal N, Hardt T, Brero A et al. MeCP2 interacts with HP1 and modulates its heterochromatin association during myogenic differentiation. Nucleic Acids Res. 35(16), 5402–5408 (2007).
  Medline CASGoogle Scholar
• 27 Dhasarathy A, Wade PA. The MBD protein family-reading an epigenetic mark? Mutat. Res. 647(1–2), 39–43 (2008).
  Medline CASGoogle Scholar
• 28 Maunakea AK, Chepelev I, Cui K, Zhao K. Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition. Cell Res. 23(11), 1256–1269 (2013).
  Medline CASGoogle Scholar
• 29 Amir RE, Van Den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23(2), 185–188 (1999).
  Medline CASGoogle Scholar
• 30 D'esposito M, Quaderi NA, Ciccodicola A et al. Isolation, physical mapping, and northern analysis of the X-linked human gene encoding methyl CpG-binding protein, MECP2. Mamm. Genome 7(7), 533–535 (1996).
  MedlineGoogle Scholar
• 31 Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY. Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Hum. Mol. Genet. 11(2), 115–124 (2002).
  Medline CASGoogle Scholar
• 32 Kokura K, Kaul SC, Wadhwa R et al. The Ski protein family is required for MeCP2-mediated transcriptional repression. J. Biol. Chem. 276(36), 34115–34121 (2001).
  Medline CASGoogle Scholar
• 33 Lyst MJ, Ekiert R, Ebert DH et al. Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. Nat. Neurosci. 16(7), 898–902 (2013).
  Medline CASGoogle Scholar
• 34 Jones PL, Veenstra GJ, Wade PA et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 19(2), 187–191 (1998).
  Medline CASGoogle Scholar
• 35 Ballas N, Grunseich C, Lu DD, Speh JC, Mandel G. REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell 121(4), 645–657 (2005).
  Medline CASGoogle Scholar
• 36 Lunyak VV, Burgess R, Prefontaine GG et al. Corepressor-dependent silencing of chromosomal regions encoding neuronal genes. Science 298(5599), 1747–1752 (2002).
  Medline CASGoogle Scholar
• 37 Harikrishnan KN, Chow MZ, Baker EK et al. Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing. Nat. Genet. 37(3), 254–264 (2005).
  Medline CASGoogle Scholar
• 38 Kimura H, Shiota K. Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, DNMT1. J. Biol. Chem. 278(7), 4806–4812 (2003).
  Medline CASGoogle Scholar
• 39 Kernohan KD, Jiang Y, Tremblay DC et al. ATRX partners with cohesin and MeCP2 and contributes to developmental silencing of imprinted genes in the brain. Dev. Cell 18(2), 191–202 (2010).
  Medline CASGoogle Scholar
• 40 Mellen M, Ayata P, Dewell S, Kriaucionis S, Heintz N. MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell 151(7), 1417–1430 (2012).• Possible binding of MeCP2 to 5-hmC.
  Medline CASGoogle Scholar
• 41 Szulwach KE, Li X, Li Y et al. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat. Neurosci. 14(12), 1607–1616 (2011).
  Medline CASGoogle Scholar
• 42 Vaute O, Nicolas E, Vandel L, Trouche D. Functional and physical interaction between the histone methyl transferase Suv39H1 and histone deacetylases. Nucleic Acids Res. 30(2), 475–481 (2002).
  Medline CASGoogle Scholar
• 43 Villa R, Morey L, Raker VA et al. The methyl-CpG binding protein MBD1 is required for PML-RARalpha function. Proc. Natl Acad. Sci. USA 103(5), 1400–1405 (2006).
  Medline CASGoogle Scholar
• 44 Fujita N, Watanabe S, Ichimura T et al. Methyl-CpG binding domain 1 (MBD1) interacts with the Suv39h1-HP1 heterochromatic complex for DNA methylation-based transcriptional repression. J. Biol. Chem. 278(26), 24132–24138 (2003).
  Medline CASGoogle Scholar
• 45 Sarraf SA, Stancheva I. Methyl-CpG binding protein MBD1 couples histone H3 methylation at lysine 9 by SETDB1 to DNA replication and chromatin assembly. Mol. Cell 15(4), 595–605 (2004).
  Medline CASGoogle Scholar
• 46 Ichimura T, Watanabe S, Sakamoto Y, Aoto T, Fujita N, Nakao M. Transcriptional repression and heterochromatin formation by MBD1 and MCAF/AM family proteins. J. Biol. Chem. 280(14), 13928–13935 (2005).
  Medline CASGoogle Scholar
• 47 Fujita N, Watanabe S, Ichimura T et al. MCAF mediates MBD1-dependent transcriptional repression. Mol. Cell. Biol. 23(8), 2834–2843 (2003).
  Medline CASGoogle Scholar
• 48 Uchimura Y, Ichimura T, Uwada J et al. Involvement of SUMO modification in MBD1- and MCAF1-mediated heterochromatin formation. J. Biol. Chem. 281(32), 23180–23190 (2006).
  Medline CASGoogle Scholar
• 49 Gu P, Xu X, Le Menuet D, Chung AC, Cooney AJ. Differential recruitment of methyl CpG-binding domain factors and DNA methyltransferases by the orphan receptor germ cell nuclear factor initiates the repression and silencing of Oct4. Stem Cells 29(7), 1041–1051 (2011).
  MedlineGoogle Scholar
• 50 Le Guezennec X, Vermeulen M, Brinkman AB et al. MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical and functional properties. Mol. Cell. Biol. 26(3), 843–851 (2006).
  Medline CASGoogle Scholar
• 51 Ramirez J, Dege C, Kutateladze TG, Hagman J. MBD2 and multiple domains of CHD4 are required for transcriptional repression by Mi-2/NuRD complexes. Mol. Cell. Biol. 32(24), 5078–5088 (2012).
  Medline CASGoogle Scholar
• 52 Marhold J, Brehm A, Kramer K. The Drosophila methyl-DNA binding protein MBD2/3 interacts with the NuRD complex via p55 and MI-2. BMC Mol. Biol. 5(1), 20 (2004).
  MedlineGoogle Scholar
• 53 Brackertz M, Boeke J, Zhang R, Renkawitz R. Two highly related p66 proteins comprise a new family of potent transcriptional repressors interacting with MBD2 and MBD3. J. Biol. Chem. 277(43), 40958–40966 (2002).
  Medline CASGoogle Scholar
• 54 Brackertz M, Gong Z, Leers J, Renkawitz R. p66alpha and p66beta of the Mi-2/NuRD complex mediate MBD2 and histone interaction. Nucleic Acids Res. 34(2), 397–406 (2006).
  Medline CASGoogle Scholar
• 55 Sekimata M, Takahashi A, Murakami-Sekimata A, Homma Y. Involvement of a novel zinc finger protein, MIZF, in transcriptional repression by interacting with a methyl-CpG-binding protein, MBD2. J. Biol. Chem. 276(46), 42632–42638 (2001).
  Medline CASGoogle Scholar
• 56 Tan CP, Nakielny S. Control of the DNA methylation system component MBD2 by protein arginine methylation. Mol. Cell. Biol. 26(19), 7224–7235 (2006).
  Medline CASGoogle Scholar
• 57 Feng Q, Zhang Y. The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev. 15(7), 827–832 (2001).
  Medline CASGoogle Scholar
• 58 Tatematsu KI, Yamazaki T, Ishikawa F. MBD2-MBD3 complex binds to hemi-methylated DNA and forms a complex containing DNMT1 at the replication foci in late S phase. Genes Cells 5(8), 677–688 (2000).
  Medline CASGoogle Scholar
• 59 Angrisano T, Lembo F, Pero R et al. TACC3 mediates the association of MBD2 with histone acetyltransferases and relieves transcriptional repression of methylated promoters. Nucleic Acids Res. 34(1), 364–372 (2006).
  Medline CASGoogle Scholar
• 60 Baubec T, Ivanek R, Lienert F, Schubeler D. Methylation-dependent and -independent genomic targeting principles of the MBD protein family. Cell 153(2), 480–492 (2013).•• Extensive genome-wide mapping of MBD family binding specificity in mouse cells and tissues.
  Medline CASGoogle Scholar
• 61 Gunther K, Rust M, Leers J et al. Differential roles for MBD2 and MBD3 at methylated CpG islands, active promoters and binding to exon sequences. Nucleic Acids Res. 41(5), 3010–3021 (2013).
  MedlineGoogle Scholar
• 62 Stefanska B, Suderman M, Machnes Z, Bhattacharyya B, Hallett M, Szyf M. Transcription onset of genes critical in liver carcinogenesis is epigenetically regulated by methylated DNA-binding protein MBD2. Carcinogenesis 34(12), 2738–2749 (2013).
  Medline CASGoogle Scholar
• 63 Fujita H, Fujii R, Aratani S, Amano T, Fukamizu A, Nakajima T. Antithetic effects of MBD2a on gene regulation. Mol. Cell. Biol. 23(8), 2645–2657 (2003).
  Medline CASGoogle Scholar
• 64 Kaji K, Caballero IM, Macleod R, Nichols J, Wilson VA, Hendrich B. The NuRD component Mbd3 is required for pluripotency of embryonic stem cells. Nat. Cell Biol. 8(3), 285–292 (2006).
  Medline CASGoogle Scholar
• 65 Morey L, Brenner C, Fazi F et al. MBD3, a component of the NuRD complex, facilitates chromatin alteration and deposition of epigenetic marks. Mol. Cell. Biol. 28(19), 5912–5923 (2008).
  Medline CASGoogle Scholar
• 66 Choi WI, Jeon BN, Yoon JH et al. The proto-oncoprotein FBI-1 interacts with MBD3 to recruit the Mi-2/NuRD-HDAC complex and BCoR and to silence p21WAF/CDKN1A by DNA methylation. Nucleic Acids Res. 41(13), 6403–6420 (2013).
  Medline CASGoogle Scholar
• 67 Aguilera C, Nakagawa K, Sancho R, Chakraborty A, Hendrich B, Behrens A. c-Jun N-terminal phosphorylation antagonises recruitment of the Mbd3/NuRD repressor complex. Nature 469(7329), 231–235 (2011).
  Medline CASGoogle Scholar
• 68 Reynolds N, Salmon-Divon M, Dvinge H et al. NuRD-mediated deacetylation of H3K27 facilitates recruitment of Polycomb Repressive Complex 2 to direct gene repression. EMBO J. 31(3), 593–605 (2012).
  Medline CASGoogle Scholar
• 69 Whyte WA, Bilodeau S, Orlando DA et al. Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. Nature 482(7384), 221–225 (2012).
  Medline CASGoogle Scholar
• 70 Wang Y, Zhang H, Chen Y et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138(4), 660–672 (2009).
  Medline CASGoogle Scholar
• 71 Shimbo T, Du Y, Grimm SA et al. MBD3 localizes at promoters, gene bodies and enhancers of active genes. PLoS Genet. 9(12), e1004028 (2013).
  MedlineGoogle Scholar
• 72 Reynolds N, Latos P, Hynes-Allen A et al. NuRD suppresses pluripotency gene expression to promote transcriptional heterogeneity and lineage commitment. Cell Stem Cell 10(5), 583–594 (2012).
  Medline CASGoogle Scholar
• 73 Yildirim O, Li R, Hung JH et al. Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells. Cell 147(7), 1498–1510 (2011).
  Medline CASGoogle Scholar
• 74 Cai Y, Geutjes EJ, De Lint K et al. The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes. Oncogene 33(17), 2157–2168 (2014).
  Medline CASGoogle Scholar
• 75 Kondo E, Gu Z, Horii A, Fukushige S. The thymine DNA glycosylase MBD4 represses transcription and is associated with methylated p16(INK4a) and hMLH1 genes. Mol. Cell. Biol. 25(11), 4388–4396 (2005).
  Medline CASGoogle Scholar
• 76 Bellacosa A, Cicchillitti L, Schepis F et al. MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA mismatch repair protein MLH1. Proc. Natl Acad. Sci. USA 96(7), 3969–3974 (1999).
  Medline CASGoogle Scholar
• 77 Laget S, Miotto B, Chin HG et al. MBD4 cooperates with DNMT1 to mediate methyl-DNA repression and protects mammalian cells from oxidative stress. Epigenetics 9(4), 546–556 (2014).
  Medline CASGoogle Scholar
• 78 Boland MJ, Christman JK. Characterization of DNMT3b:thymine-DNA glycosylase interaction and stimulation of thymine glycosylase-mediated repair by DNA methyltransferase(s) and RNA. J. Mol. Biol. 379(3), 492–504 (2008).
  Medline CASGoogle Scholar
• 79 Rai K, Huggins IJ, James SR, Karpf AR, Jones DA, Cairns BR. DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, and gadd45. Cell 135(7), 1201–1212 (2008).• MBD4 as a potential demethylator.
  Medline CASGoogle Scholar
• 80 Cortellino S, Xu J, Sannai M et al. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 146(1), 67–79 (2011).
  Medline CASGoogle Scholar
• 81 Hashimoto H, Zhang X, Cheng X. Excision of thymine and 5-hydroxymethyluracil by the MBD4 DNA glycosylase domain: structural basis and implications for active DNA demethylation. Nucleic Acids Res. 40(17), 8276–8284 (2012).
  Medline CASGoogle Scholar
• 82 Bienvenu T, Chelly J. Molecular genetics of Rett syndrome: when DNA methylation goes unrecognized. Nat. Rev. Genet. 7(6), 415–426 (2006).
  Medline CASGoogle Scholar
• 83 Zhou Z, Qin J, Tang J et al. Down-regulation of MeCP2 in Hirschsprung's disease. J. Pediatr. Surg. 48(10), 2099–2105 (2013).
  MedlineGoogle Scholar
• 84 Carney RM, Wolpert CM, Ravan SA et al. Identification of MeCP2 mutations in a series of females with autistic disorder. Pediatr. Neurol. 28(3), 205–211 (2003).
  MedlineGoogle Scholar
• 85 Loat CS, Curran S, Lewis CM et al. Methyl-CpG-binding protein 2 polymorphisms and vulnerability to autism. Genes Brain Behav. 7(7), 754–760 (2008).
  Medline CASGoogle Scholar
• 86 Nagarajan RP, Hogart AR, Gwye Y, Martin MR, Lasalle JM. Reduced MeCP2 expression is frequent in autism frontal cortex and correlates with aberrant MECP2 promoter methylation. Epigenetics 1(4), e1–e11 (2006).
  MedlineGoogle Scholar
• 87 Shibayama A, Cook EH Jr, Feng J et al. MECP2 structural and 3’-UTR variants in schizophrenia, autism and other psychiatric diseases: a possible association with autism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 128B(1), 50–53 (2004).
  MedlineGoogle Scholar
• 88 Ramocki MB, Peters SU, Tavyev YJ et al. Autism and other neuropsychiatric symptoms are prevalent in individuals with MeCP2 duplication syndrome. Ann. Neurol. 66(6), 771–782 (2009).
  Medline CASGoogle Scholar
• 89 Muller HM, Fiegl H, Goebel G et al. MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status. Br. J. Cancer 89(10), 1934–1939 (2003).
  Medline CASGoogle Scholar
• 90 Cukier HN, Rabionet R, Konidari I et al. Novel variants identified in methyl-CpG-binding domain genes in autistic individuals. Neurogenetics 11(3), 291–303 (2010).
  Medline CASGoogle Scholar
• 91 Liu H, Jin G, Wang H et al. Methyl-CpG binding domain 1 gene polymorphisms and lung cancer risk in a Chinese population. Biomarkers 13(6), 607–617 (2008).
  Medline CASGoogle Scholar
• 92 Bader S, Walker M, Mcqueen HA et al. MBD1, MBD2 and CGBP genes at chromosome 18q21 are infrequently mutated in human colon and lung cancers. Oncogene 22(22), 3506–3510 (2003).
  Medline CASGoogle Scholar
• 93 Jang JS, Lee SJ, Choi JE et al. Methyl-CpG binding domain 1 gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol. Biomarkers Prev. 14(11 Pt 1), 2474–2480 (2005).
  Medline CASGoogle Scholar
• 94 Ghersi D, Singh M. Interaction-based discovery of functionally important genes in cancers. Nucleic Acids Res. 42(3), e18 (2014).
  Medline CASGoogle Scholar
• 95 Xu J, Zhu W, Xu W et al. Up-regulation of MBD1 promotes pancreatic cancer cell epithelial-mesenchymal transition and invasion by epigenetic down-regulation of E-cadherin. Curr. Mol. Med. 13(3), 387–400 (2013).
  Medline CASGoogle Scholar
• 96 Xu J, Zhu W, Xu W et al. Silencing of MBD1 reverses pancreatic cancer therapy resistance through inhibition of DNA damage repair. Int. J. Oncol. 42(6), 2046–2052 (2013).
  Medline CASGoogle Scholar
• 97 Patra SK, Patra A, Zhao H, Carroll P, Dahiya R. Methyl-CpG-DNA binding proteins in human prostate cancer: expression of CXXC sequence containing MBD1 and repression of MBD2 and MeCP2. Biochem. Biophys. Res. Commun. 302(4), 759–766 (2003).
  Medline CASGoogle Scholar
• 98 Pontes TB, Chen ES, Gigek CO et al. Reduced mRNA expression levels of MBD2 and MBD3 in gastric carcinogenesis. Tumour Biol. 35(4), 3447–3453 (2014).
  Medline CASGoogle Scholar
• 99 He M, Fan J, Jiang R, Tang WX, Wang ZW. Expression of DNMTs and MBD2 in GIST. Biomed. Rep. 1(2), 223–227 (2013).
  Medline CASGoogle Scholar
• 100 Billard LM, Magdinier F, Lenoir GM, Frappart L, Dante R. MeCP2 and MBD2 expression during normal and pathological growth of the human mammary gland. Oncogene 21(17), 2704–2712 (2002).
  Medline CASGoogle Scholar
• 101 Sapkota Y, Robson P, Lai R, Cass CE, Mackey JR, Damaraju S. A two-stage association study identifies methyl-CpG-binding domain protein 2 gene polymorphisms as candidates for breast cancer susceptibility. Eur. J. Hum. Genet. 20(6), 682–689 (2012).
  Medline CASGoogle Scholar
• 102 Zhu Y, Brown HN, Zhang Y, Holford TR, Zheng T. Genotypes and haplotypes of the methyl-CpG-binding domain 2 modify breast cancer risk dependent upon menopausal status. Breast Cancer Res. 7(5), R745–R752 (2005).
  Medline CASGoogle Scholar
• 103 Zhu D, Hunter SB, Vertino PM, Van Meir EG. Overexpression of MBD2 in glioblastoma maintains epigenetic silencing and inhibits the antiangiogenic function of the tumor suppressor gene BAI1. Cancer Res. 71(17), 5859–5870 (2011).
  Medline CASGoogle Scholar
• 104 Balada E, Ordi-Ros J, Serrano-Acedo S, Martinez-Lostao L, Vilardell-Tarres M. Transcript overexpression of the MBD2 and MBD4 genes in CD4⁺ T cells from systemic lupus erythematosus patients. J. Leukoc. Biol. 81(6), 1609–1616 (2007).
  Medline CASGoogle Scholar
• 105 Qin HH, Zhu XH, Liang J et al. Associations between aberrant DNA methylation and transcript levels of DNMT1 and MBD2 in CD4⁺ T cells from patients with systemic lupus erythematosus. Australas. J. Dermatol. 54(2), 90–95 (2013).
  MedlineGoogle Scholar
• 106 Chen ZP, Gu DS, Zhou ZP et al. Decreased expression of MBD2 and MBD4 gene and genomic-wide hypomethylation in patients with primary immune thrombocytopenia. Hum. Immunol. 72(6), 486–491 (2011).
  Medline CASGoogle Scholar
• 107 Zhao S, Choi M, Overton JD et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc. Natl Acad. Sci. USA 110(8), 2916–2921 (2013).
  Medline CASGoogle Scholar
• 108 Schlegel J, Guneysu S, Mennel HD. Expression of the genes of methyl-binding domain proteins in human gliomas. Oncol. Rep. 9(2), 393–395 (2002).
  Medline CASGoogle Scholar
• 109 Bader S, Walker M, Hendrich B et al. Somatic frameshift mutations in the MBD4 gene of sporadic colon cancers with mismatch repair deficiency. Oncogene 18(56), 8044–8047 (1999).
  Medline CASGoogle Scholar
• 110 Riccio A, Aaltonen LA, Godwin AK et al. The DNA repair gene MBD4 (MED1) is mutated in human carcinomas with microsatellite instability. Nat. Genet. 23(3), 266–268 (1999).
  Medline CASGoogle Scholar
• 111 Yamada T, Koyama T, Ohwada S et al. Frameshift mutations in the MBD4/MED1 gene in primary gastric cancer with high-frequency microsatellite instability. Cancer Lett. 181(1), 115–120 (2002).
  Medline CASGoogle Scholar
• 112 Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H, Hirohashi S. Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology 33(3), 561–568 (2001).
  Medline CASGoogle Scholar
• 113 Cukier HN, Lee JM, Ma D et al. The expanding role of MBD genes in autism: identification of a MECP2 duplication and novel alterations in MBD5, MBD6, and SETDB1. Autism Res. 5(6), 385–397 (2012).
  MedlineGoogle Scholar
• 114 Hamdan FF, Srour M, Capo-Chichi JM et al. De novo mutations in moderate or severe intellectual disability. PLoS Genet. 10(10), e1004772 (2014).
  MedlineGoogle Scholar
• 115 Mullegama SV, Rosenfeld JA, Orellana C et al. Reciprocal deletion and duplication at 2q23.1 indicates a role for MBD5 in autism spectrum disorder. Eur. J. Hum. Genet. 22(1), 57–63 (2014).
  Medline CASGoogle Scholar
• 116 Jørgensen HF, Ben-Porath I, Bird AP. MBD1 is recruited to both methylated and nonmethylated CpGs via distinct DNA binding domains. Mol. Cell. Biol. 24(8), 3387–3395 (2004).
  Medline CASGoogle Scholar
• 117 Zhao X, Ueba T, Christie BR et al. Mice lacking methyl-CpG binding protein 1 have deficits in adult neurogenesis and hippocampal function. Proc. Natl Acad. Sci. USA 100(11), 6777–6782 (2003).
  Medline CASGoogle Scholar
• 118 Roloff TC, Ropers HH, Nuber UA. Comparative study of methyl-CpG-binding domain proteins. BMC Genomics 4(1), 1 (2003).
  MedlineGoogle Scholar
• 119 Gnanapragasam MN, Scarsdale JN, Amaya ML et al. p66Alpha-MBD2 coiled-coil interaction and recruitment of Mi-2 are critical for globin gene silencing by the MBD2-NuRD complex. Proc. Natl Acad. Sci. USA 108(18), 7487–7492 (2011).
  Medline CASGoogle Scholar
• 120 Becker A, Allmann L, Hofstatter M et al. Direct homo- and hetero-interactions of MeCP2 and MBD2. PLoS ONE 8(1), e53730 (2013).
  Medline CASGoogle Scholar
• 121 Ng HH, Zhang Y, Hendrich B et al. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat. Genet. 23(1), 58–61 (1999).
  Medline CASGoogle Scholar
• 122 Hendrich B, Guy J, Ramsahoye B, Wilson VA, Bird A. Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. Genes Dev. 15(6), 710–723 (2001).
  Medline CASGoogle Scholar
• 123 Saito M, Ishikawa F. The mCpG-binding domain of human MBD3 does not bind to mCpG but interacts with NuRD/Mi2 components HDAC1 and MTA2. J. Biol. Chem. 277(38), 35434–35439 (2002).
  Medline CASGoogle Scholar
• 124 Petronzelli F, Riccio A, Markham GD et al. Investigation of the substrate spectrum of the human mismatch-specific DNA N-glycosylase MED1 (MBD4): fundamental role of the catalytic domain. J. Cell. Physiol. 185(3), 473–480 (2000).
  Medline CASGoogle Scholar
• 125 Hendrich B, Hardeland U, Ng H-H, Jiricny J, Bird A. The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. Nature 401(6750), 301–304 (1999).
  Medline CASGoogle Scholar
• 126 Wong E, Yang K, Kuraguchi M et al. MBD4 inactivation increases C right-arrowT transition mutations and promotes gastrointestinal tumor formation. Proc. Natl Acad. Sci. USA 99(23), 14937–14942 (2002).
  Medline CASGoogle Scholar
• 127 Laget S, Joulie M, Le Masson F et al. The human proteins MBD5 and MBD6 associate with heterochromatin but they do not bind methylated DNA. PLoS ONE 5(8), e11982 (2010).
  MedlineGoogle Scholar
• 128 Qin S, Min J. Structure and function of the nucleosome-binding PWWP domain. Trends Biochem. Sci. 39(11), 536–547 (2014).
  Medline CASGoogle Scholar
• 129 Jung JS, Jee MK, Cho HT et al. MBD6 is a direct target of Oct4 and controls the stemness and differentiation of adipose tissue-derived stem cells. Cell. Mol. Life Sci. 70(4), 711–728 (2013).
  Medline CASGoogle Scholar
• 130 Falandry C, Fourel G, Galy V et al. CLLD8/KMT1F is a lysine methyltransferase that is important for chromosome segregation. J. Biol. Chem. 285(26), 20234–20241 (2010).
  Medline CASGoogle Scholar
• 131 Schultz DC, Ayyanathan K, Negorev D, Maul GG, Rauscher FJ, 3rd. SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev. 16(8), 919–932 (2002).
  Medline CASGoogle Scholar
• 132 Jones MH, Hamana N, Nezu J, Shimane M. A novel family of bromodomain genes. Genomics 63(1), 40–45 (2000).
  Medline CASGoogle Scholar
• 133 Loyola A, Tagami H, Bonaldi T et al. The HP1alpha-CAF1-SetDB1-containing complex provides H3K9me1 for Suv39-mediated K9me3 in pericentric heterochromatin. EMBO Rep. 10(7), 769–775 (2009).
  Medline CASGoogle Scholar
• 134 Strohner R, Nemeth A, Jansa P et al. NoRC – a novel member of mammalian ISWI-containing chromatin remodeling machines. EMBO J. 20(17), 4892–4900 (2001).
  Medline CASGoogle Scholar
• 135 Santoro R, Grummt I. Epigenetic mechanism of rRNA gene silencing: temporal order of NoRC-mediated histone modification, chromatin remodeling, and DNA methylation. Mol. Cell. Biol. 25(7), 2539–2546 (2005).
  Medline CASGoogle Scholar
• 136 Cramer JM, Scarsdale JN, Walavalkar NM, Buchwald WA, Ginder GD, Williams DC. Probing the dynamic distribution of bound states for methyl-cytosine binding domains on DNA. J. Biol. Chem. 289(3), 1294–1302 (2013).
  MedlineGoogle Scholar
• 137 Fraga MF, Ballestar E, Montoya G, Taysavang P, Wade PA, Esteller M. The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic Acids Res. 31(6), 1765–1774 (2003).
  Medline CASGoogle Scholar
• 138 Hashimoto H, Liu Y, Upadhyay AK et al. Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation. Nucleic Acids Res. 40(11), 4841–4849 (2012).
  Medline CASGoogle Scholar
• 139 Valinluck V, Tsai HH, Rogstad DK, Burdzy A, Bird A, Sowers LC. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Res. 32(14), 4100–4108 (2004).
  Medline CASGoogle Scholar
• 140 Spruijt CG, Gnerlich F, Smits AH et al. Dynamic readers for 5-(hydroxy) methylcytosine and its oxidized derivatives. Cell 152(5), 1146–1159 (2013).
  Medline CASGoogle Scholar
• 141 Gabel HW, Kinde B, Stroud H et al. Disruption of DNA-methylation-dependent long gene repression in Rett syndrome. Nature doi:10.1038/nature14319 (2015) (Epub ahead of print).
  MedlineGoogle Scholar
• 142 Nestor CE, Ottaviano R, Reddington J et al. Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. Genome Res. 22(3), 467–477 (2012).
  Medline CASGoogle Scholar
• 143 Chatagnon A, Perriaud L, Nazaret N et al. Preferential binding of the methyl-CpG binding domain protein 2 at methylated transcriptional start site regions. Epigenetics 6(11), 1295–1307 (2011).
  Medline CASGoogle Scholar
• 144 Menafra R, Brinkman AB, Matarese F et al. Genome-wide binding of MBD2 reveals strong preference for highly methylated loci. PLoS ONE 9(6), e99603 (2014).
  MedlineGoogle Scholar
• 145 Skene PJ, Illingworth RS, Webb S et al. Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol. Cell 37(4), 457–468 (2010).
  Medline CASGoogle Scholar
• 146 Mayer C, Schmitz KM, Li J, Grummt I, Santoro R. Intergenic transcripts regulate the epigenetic state of rRNA genes. Mol. Cell 22(3), 351–361 (2006).
  Medline CASGoogle Scholar
• 147 Jeffery L, Nakielny S. Components of the DNA methylation system of chromatin control are RNA-binding proteins. J. Biol. Chem. 279(47), 49479–49487 (2004).
  Medline CASGoogle Scholar
• 148 Grewal SI, Jia S. Heterochromatin revisited. Nat. Rev. Genet. 8(1), 35–46 (2007).
  Medline CASGoogle Scholar
• 149 Brero A, Easwaran HP, Nowak D et al. Methyl CpG-binding proteins induce large-scale chromatin reorganization during terminal differentiation. J. Cell Biol. 169(5), 733–743 (2005).
  Medline CASGoogle Scholar
• 150 Casas-Delucchi CS, Becker A, Bolius JJ, Cardoso MC. Targeted manipulation of heterochromatin rescues MeCP2 Rett mutants and re-establishes higher order chromatin organization. Nucleic Acids Res. 40(22), e176 (2012).
  Medline CASGoogle Scholar
• 151 Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet. 10(5), 295–304 (2009).
  Medline CASGoogle Scholar
• 152 Sakamoto Y, Watanabe S, Ichimura T et al. Overlapping roles of the methylated DNA-binding protein MBD1 and polycomb group proteins in transcriptional repression of HOXA genes and heterochromatin foci formation. J. Biol. Chem. 282(22), 16391–16400 (2007).
  Medline CASGoogle Scholar
• 153 Minkovsky A, Sahakyan A, Rankin-Gee E, Bonora G, Patel S, Plath K. The MBD1-Atf7ip-Setdb1 pathway contributes to the maintenance of X chromosome inactivation. Epigenetics Chromatin 7, 12 (2014).
  MedlineGoogle Scholar
• 154 Singleton MK, Gonzales ML, Leung KN et al. MeCP2 is required for global heterochromatic and nucleolar changes during activity-dependent neuronal maturation. Neurobiol. Dis. 43(1), 190–200 (2011).
  Medline CASGoogle Scholar
• 155 Shahbazian M, Young J, Yuva-Paylor L et al. Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron 35(2), 243–254 (2002).
  Medline CASGoogle Scholar
• 156 Meehan RR, Lewis JD, Mckay S, Kleiner EL, Bird AP. Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs. Cell 58(3), 499–507 (1989).•• Discovery of the first mammalian MBD protein.
  Medline CASGoogle Scholar
• 157 Magdinier F, Wolffe AP. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. Proc. Natl Acad. Sci. USA 98(9), 4990–4995 (2001).• One of the first papers describing MBD protein-associated silencing of hypermethylated CpGi promoters of tumor-suppressor genes in cancer.
  Medline CASGoogle Scholar
• 158 Lin X, Nelson WG. Methyl-CpG-binding domain protein-2 mediates transcriptional repression associated with hypermethylated GSTP1 CpG islands in MCF-7 breast cancer cells. Cancer Res. 63(2), 498–504 (2003).
  Medline CASGoogle Scholar
• 159 Zhao Q, Rank G, Tan YT et al. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat. Struct. Mol. Biol. 16(3), 304–311 (2009).
  Medline CASGoogle Scholar
• 160 Di Lorenzo A, Bedford MT. Histone arginine methylation. FEBS Lett. 585(13), 2024–2031 (2011).
  Medline CASGoogle Scholar
• 161 Wang H, Huang ZQ, Xia L et al. Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor. Science 293(5531), 853–857 (2001).
  Medline CASGoogle Scholar
• 162 Pal S, Vishwanath SN, Erdjument-Bromage H, Tempst P, Sif S. Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor-suppressor genes. Mol. Cell. Biol. 24(21), 9630–9645 (2004).
  Medline CASGoogle Scholar
• 163 Becker PB, Workman JL. Nucleosome remodeling and epigenetics. Cold Spring Harb. Perspect. Biol. 5(9), a017905 (2013).
  MedlineGoogle Scholar
• 164 Song JZ, Stirzaker C, Harrison J, Melki JR, Clark SJ. Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene 21(7), 1048–1061 (2002).
  Medline CASGoogle Scholar
• 165 Stirzaker C, Song JZ, Davidson B, Clark SJ. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res. 64(11), 3871–3877 (2004).
  Medline CASGoogle Scholar
• 166 Pombo A, Dillon N. Three-dimensional genome architecture: players and mechanisms. Nat. Rev. Mol. Cell Biol. 16(4), 245–257 (2015).
  Medline CASGoogle Scholar
• 167 Georgel PT, Horowitz-Scherer RA, Adkins N, Woodcock CL, Wade PA, Hansen JC. Chromatin compaction by human MeCP2. Assembly of novel secondary chromatin structures in the absence of DNA methylation. J. Biol. Chem. 278(34), 32181–32188 (2003).
  Medline CASGoogle Scholar
• 168 Nikitina T, Shi X, Ghosh RP, Horowitz-Scherer RA, Hansen JC, Woodcock CL. Multiple modes of interaction between the methylated DNA binding protein MeCP2 and chromatin. Mol. Cell. Biol. 27(3), 864–877 (2007).
  Medline CASGoogle Scholar
• 169 Stuss DP, Cheema M, Ng MK et al. Impaired in vivo binding of MeCP2 to chromatin in the absence of its DNA methyl-binding domain. Nucleic Acids Res. 41(9), 4888–4900 (2013).
  Medline CASGoogle Scholar
• 170 Horike S, Cai S, Miyano M, Cheng JF, Kohwi-Shigematsu T. Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome. Nat. Genet. 37(1), 31–40 (2005).
  Medline CASGoogle Scholar
• 171 Nan X, Hou J, Maclean A et al. Interaction between chromatin proteins MECP2 and ATRX is disrupted by mutations that cause inherited mental retardation. Proc. Natl Acad. Sci. USA 104(8), 2709–2714 (2007).
  Medline CASGoogle Scholar
• 172 Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet. 25(3), 269–277 (2000).
  Medline CASGoogle Scholar
• 173 Shibahara K, Stillman B. Replication-dependent marking of DNA by PCNA facilitates CAF-1-coupled inheritance of chromatin. Cell 96(4), 575–585 (1999).
  Medline CASGoogle Scholar
• 174 Lu Y, Loh YH, Li H et al. Alternative splicing of MBD2 supports self-renewal in human pluripotent stem cells. Cell Stem Cell 15(1), 92–101 (2014).
  Medline CASGoogle Scholar
• 175 Rais Y, Zviran A, Geula S et al. Deterministic direct reprogramming of somatic cells to pluripotency. Nature 502(7469), 65–70 (2013).• KD of MBD3 vastly improves reprogramming efficiency of human fibroblasts to induced pluripotent stem cells.
  Medline CASGoogle Scholar
• 176 Shimoda N, Hirose K, Kaneto R et al. No evidence for AID/MBD4-coupled DNA demethylation in zebrafish embryos. PLoS ONE 9(12), e114816 (2014).
  MedlineGoogle Scholar
• 177 Cunha S, Lin YC, Goossen EA et al. The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming. Cell Rep. 6(1), 141–154 (2014).
  Medline CASGoogle Scholar
• 178 Pulukuri S, Rao JS. CpG island promoter methylation and silencing of 14–3–3σ gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2. Oncogene 25(33), 4559–4572 (2006).
  Medline CASGoogle Scholar
• 179 Chatagnon A, Bougel S, Perriaud L, Lachuer J, Benhattar J, Dante R. Specific association between the methyl-CpG-binding domain protein 2 and the hypermethylated region of the human telomerase reverse transcriptase promoter in cancer cells. Carcinogenesis 30(1), 28–34 (2009).
  Medline CASGoogle Scholar
• 180 Lopez-Serra L, Ballestar E, Fraga MF, Alaminos M, Setien F, Esteller M. A profile of methyl-CpG binding domain protein occupancy of hypermethylated promoter CpG islands of tumor suppressor genes in human cancer. Cancer Res. 66(17), 8342–8346 (2006).
  Medline CASGoogle Scholar
• 181 Sansom OJ, Berger J, Bishop SM, Hendrich B, Bird A, Clarke AR. Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nat. Genet. 34(2), 145–147 (2003).
  Medline CASGoogle Scholar
• 182 Hodge JC, Mitchell E, Pillalamarri V et al. Disruption of MBD5 contributes to a spectrum of psychopathology and neurodevelopmental abnormalities. Mol. Psychiatry 19(3), 368–379 (2014).
  Medline CASGoogle Scholar
• 183 Talkowski ME, Mullegama SV, Rosenfeld JA et al. Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder. Am. J. Hum. Genet. 89(4), 551–563 (2011).
  Medline CASGoogle Scholar
• 184 Williams SR, Mullegama SV, Rosenfeld JA et al. Haploinsufficiency of MBD5 associated with a syndrome involving microcephaly, intellectual disabilities, severe speech impairment, and seizures. Eur. J. Hum. Genet. 18(4), 436–441 (2010).
  MedlineGoogle Scholar
• 185 Cerami E, Gao J, Dogrusoz U et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2(5), 401–404 (2012).
  MedlineGoogle Scholar
• 186 Gao J, Aksoy BA, Dogrusoz U et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6(269), pl1 (2013).
  MedlineGoogle Scholar
• 187 Desai MA, Webb HD, Sinanan LM et al. An intrinsically disordered region of methyl-CpG binding domain protein 2 (MBD2) recruits the histone deacetylase core of the NuRD complex. Nucleic Acids Res. 43(6), 3100–3113 (2015).
  Medline CASGoogle Scholar
• 188 The Cancer Genome Atlas (TCGA). http://cancergenome.nih.gov
  Google Scholar
• 189 cBioPortal for Cancer Genomics. www.cbioportal.org/public-portal/
  Google Scholar
• 190 cBioPortal for Cancer Genomics: MBD1. http://bit.ly/15Opeso
  Google Scholar
• 191 cBioPortal for Cancer Genomics: MBD2. http://bit.ly/1zR4Jou
  Google Scholar
• 192 cBioPortal for Cancer Genomics: MBD3. http://bit.ly/15OplEn
  Google Scholar
• 193 cBioPortal for Cancer Genomics: MBD4. http://bit.ly/1zgXlSs
  Google Scholar
• 194 cBioPortal for Cancer Genomics: MeCP2. http://bit.ly/1vkwzth
  Google Scholar
• 195 Miquel C, Jacob S, Grandjouan S et al. Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability. Oncogene 26(40), 5919–5926 (2007).
  Medline CASGoogle Scholar
• 196 Khrapunov S, Warren C, Cheng H, Berko ER, Greally JM, Brenowitz M. Unusual characteristics of the DNA binding domain of epigenetic regulatory protein MeCP2 determine its binding specificity. Biochemistry (Mosc.) 53(21), 3379–3391 (2014).
  Medline CASGoogle Scholar
• 197 Landau DA, Clement K, Ziller MJ et al. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell 26(6), 813–825 (2014).
  Medline CASGoogle Scholar